CP, bavi given a lot of coverage in this 2-pager on I/O. Notice that P3 "faltered" a much richer and honest appraisal of that trial ending than given by some here. Also this...
Gabrilovich is involved in several clinical studies focused on MDSC strategies, although he did not want to discuss the details of those efforts.